Imaginir works with mid-tier Korean beauty brands at the exact point where marketing meets regulation, in the US and the EU alike: the claims, classification, and Responsible Person decisions that determine whether a shipment clears the border, or a product stays on the shelf.
A structured, brand-specific review of your product claims, label copy, and marketing language against current FDA cosmetic-vs-drug classification rules and the EU Cosmetics Regulation (EC 1223/2009), including Annex II/III ingredient restrictions. Two markets, two different failure modes — a claim that reads as a US drug claim, and a formulation that reads as an EU-restricted ingredient — reviewed together, not separately.
This is not a substitute for legal review — it's the brand-specific, claims-language pass that neither your import broker nor a general compliance checklist is built to do.
The EU path to shelf runs through a chain most Korean brands have never had to navigate end to end: an EU Responsible Person, a Product Information File (PIF), a Cosmetic Product Safety Report (CPSR) from a qualified safety assessor, CPNP notification, EU-compliant labeling, and increasingly, packaging and EPR obligations under the EU's Packaging and Packaging Waste Regulation. The US path is shorter but not simple either: MoCRA facility and product registration, state-level requirements like California's Prop 65, and importer-of-record structuring.
Imaginir doesn't perform this regulated technical work itself — we're not your safety assessor, and we're not your Responsible Person. What we do is act as the single point of coordination: building the checklist, tracking what's missing, and managing a network of qualified partners so you're not personally chasing eight vendors across two continents.
Once the compliance foundation is solid, the next question is sequencing: enter the US first, the EU first, or run both in parallel — a live, growing choice now that Europe has overtaken North America as K-beauty's top export destination. This draws on cross-market judgment — fluency in Korean brand conventions and both US and EU buyer expectations — rather than a generic market-entry template.
And "the EU" isn't one decision either: the UK and Germany run on a drugstore-mass model (Boots, Müller, dm-drogerie), France centers on premium-mass retail (Sephora, Douglas), and markets like Italy have no drugstore-mass tier at all — entry there runs through Sephora or a digital-first launch. Which country, and which retail tier, shapes the plan as much as which region does.
As the relationship develops, Imaginir makes warm introductions to pharmacies, concept stores, and distributors across the US and EU, built through direct relationships — not a cold list. This is offered as trust and track record build, not sold as part of a day-one package.
Final regulatory sign-off always routes to a licensed partner. That's true in the US, and it's true in the EU: Imaginir never acts as your appointed EU Responsible Person. For the specialized technical and legal work — EU Responsible Person services, CPSR safety assessment, packaging/EPR compliance — Imaginir coordinates you to qualified, independent partners rather than performing that work in-house. That's a deliberate choice, not a limitation: it keeps us independent and focused on judgment and project management, the part of this process most Korean brands actually lack. Engagement scope is confirmed in writing before work begins.